DREADDs: novel tools for drug discovery and development.

Since the invention of the first designer receptors exclusively activated by designer drugs (DREADDs), these engineered G protein-coupled receptors (GPCRs) have been widely applied in investigations of biological processes and behaviors. DREADD technology has emerged as a powerful tool with great potential for drug discovery and development. DREADDs can facilitate the identification of druggable targets and enable researchers to explore the activities of novel drugs against both known and orphan GPCRs. Here, we discuss how DREADDs can be used as novel tools for drug discovery and development.

[1]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[2]  H. Akil,et al.  Controlling signaling with a specifically designed Gi-coupled receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Bryan L. Roth,et al.  Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment , 2009, Molecular Pharmacology.

[4]  B. Roth,et al.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand , 2007, Proceedings of the National Academy of Sciences.

[5]  Hualiang Jiang,et al.  Structural Basis for Molecular Recognition at Serotonin Receptors , 2013, Science.

[6]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[7]  B. Conklin,et al.  Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice , 1999, Nature Biotechnology.

[8]  Bryan L Roth,et al.  Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. , 2011, Annual review of pharmacology and toxicology.

[9]  B. Roth,et al.  Pharmacosynthetics: Reimagining the pharmacogenetic approach , 2013, Brain Research.

[10]  Shuyun Dong,et al.  Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs , 2010, Nature Protocols.

[11]  A. Christopoulos.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[12]  M. Foster Olive,et al.  Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models , 2012, The Journal of Neuroscience.

[13]  M. Nicolelis,et al.  Remote Control of Neuronal Activity in Transgenic Mice Expressing Evolved G Protein-Coupled Receptors , 2009, Neuron.

[14]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[15]  T. Kenakin.  Biased signalling and allosteric machines: new vistas and challenges for drug discovery , 2012, British journal of pharmacology.

[16]  B. Conklin,et al.  Development of Hydrocephalus in Mice Expressing the Gi-Coupled GPCR Ro1 RASSL Receptor in Astrocytes , 2007, The Journal of Neuroscience.

[17]  T. Kenakin.  New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.

[18]  J. Violin,et al.  Beta-arrestin-biased ligands at seven-transmembrane receptors. , 2007, Trends in pharmacological sciences.

[19]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[20]  Jian Hua Li,et al.  A chemical-genetic approach to study G protein regulation of β cell function in vivo , 2009, Proceedings of the National Academy of Sciences.

[21]  Maria F. Sassano,et al.  Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. , 2012, Journal of medicinal chemistry.

[22]  J. Violin,et al.  TRV120027, a Novel &bgr;-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure , 2012, Circulation. Heart failure.

[23]  B. Roth,et al.  Multiple mechanisms of serotonergic signal transduction. , 1987, Life sciences.

[24]  Terry Kenakin.  Functional selectivity in GPCR modulator screening. , 2008, Combinatorial chemistry & high throughput screening.

[25]  B. Roth,et al.  The expanded biology of serotonin. , 2009, Annual review of medicine.

[26]  Maria F. Sassano,et al.  Discovery of β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy , 2011, Proceedings of the National Academy of Sciences.

[27]  Bryan L Roth,et al.  Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. , 2004, Pharmacology & therapeutics.

[28]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[29]  J. Wess,et al.  Engineering GPCR signaling pathways with RASSLs , 2008, Nature Methods.

[30]  A. IJzerman,et al.  Allosteric modulation of G protein-coupled receptors. , 2001, Current opinion in drug discovery & development.

[31]  S. Majumdar,et al.  Conditional expression of a Gi-coupled receptor in osteoblasts results in trabecular osteopenia. , 2008, Endocrinology.

[32]  C. Strader,et al.  A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. , 1989, The Journal of biological chemistry.

[33]  C. Strader,et al.  Allele-specific activation of genetically engineered receptors. , 1991, The Journal of biological chemistry.

[34]  Maria F. Sassano,et al.  A Pharmacological Organization of G Protein-coupled Receptors , 2012, Nature Methods.

[35]  M. Lark,et al.  TRV120027, a Novel Beta-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure , 2011 .

[36]  R. Mailman,et al.  Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways , 2007, Neuropsychopharmacology.

[37]  K. Vranizan,et al.  Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Stevens,et al.  Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.

[39]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[40]  J. Arrowsmith.  Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[41]  B. Roth.  Irving Page Lecture: 5-HT2A serotonin receptor biology: Interacting proteins, kinases and paradoxical regulation , 2011, Neuropharmacology.

[42]  J. Violin,et al.  β-Arrestin-biased ligands at seven-transmembrane receptors , 2007 .

[43]  R. Mailman.  GPCR functional selectivity has therapeutic impact. , 2007, Trends in pharmacological sciences.

[44]  B. Roth,et al.  Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors , 2009, Front. Mol. Neurosci..